Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serlopitant for Pruritus in Prurigo Nodularis
NCT03546816Phase 3Completed
- Sponsor
- Vyne Therapeutics
- Start
- May 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of serlopitant in prurigo nodularis (PN), sponsored by Vyne Therapeutics. Primary endpoint: Percent of Subjects With Worst-Itch Numeric Rating Scale 4-point Responder at 10 weeks. Started May 2018; status: completed.
02
Drugs
serlopitant
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT03546816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546816.